Search Results

Deferiprone: Rheumatic disorders in a child: case report

Source: Reactions, Volume 1, Number 1269, 2009-09-12 , pp. 16-16(1)

Publisher: Adis International

Efalizumab: Arthropathy, oedema and skin eruption, and withdrawal leading to erythroderma: case report

Source: Reactions, Volume 1, Number 1207, 2008-06-21 , pp. 18-18(1)

Publisher: Adis International

Efalizumab: Oedema, papular eruption and arthropathy: case report

Source: Reactions, Volume 1, Number 1187, 2008-02-02 , pp. 13-14(2)

Publisher: Adis International

US Medicare recipients with arthritis may miss out on rheumatologist care, as the formula used to calculate Medicare payments to physicians, is `flawed'

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 547, 2008-02-23 , pp. 11-11(1)

Publisher: Adis International

Moxifloxacin: Rheumatic disorders (first report) in an elderly patient: case report

Source: Reactions, Volume 1, Number 1138, 2007-02-10 , pp. 19-20(2)

Publisher: Adis International

Alendronic acid tops alfacalcidol for steroid-induced osteoporosis

Source: Reactions, Volume 1, Number 1116, 2006-08-26 , pp. 3-3(1)

Publisher: Adis International

Alendronic acid tops alfacalcidol for steroid-induced osteoporosis

Source: Inpharma, Volume 1, Number 1552, 2006-08-26 , pp. 15-15(1)

Publisher: Adis International

Clopidogrel: Skin eruptions and rheumatic disorders: case report

Source: Reactions, Volume 1, Number 1100, 2006-05-06 , pp. 11-11(1)

Publisher: Adis International

Alendronic acid appears to be efficacious in the treatment of acute Charcot neuroarthropathy

Source: Inpharma, Volume 1, Number 1496, 2005-07-16 , pp. 14-14(1)

Publisher: Adis International

A consensus statement on the use of biological agents to treat rheumatic diseases has been issued

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 467, 2004-12-04 , pp. 5-5(1)

Publisher: Adis International

US costs for arthritis and other rheumatic disorders updated

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 454, 2004-06-05 , pp. 9-9(1)

Publisher: Adis International

Expense and lack of effectiveness are the most frequently reported reasons for stopping use of CAM among patients with rheumatoid conditions

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 439, 2003 , pp. 7-7(1)

Publisher: Adis International

Meloxicam frequently prescribed in rheumatic disorders

Source: Inpharma, Volume 1, Number 1375, 2003 , pp. 4-4(1)

Publisher: Adis International

Meloxicam frequently prescribed in rheumatic disorders

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 400, 2003 , pp. 5-5(1)

Publisher: Adis International

Rheumatologists in Canada encounter a number of barriers to providing adequate care

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 394, 2003 , pp. 5-5(1)

Publisher: Adis International

Indinavir: Rheumatological disorders: 4 case reports

Source: Reactions, Volume 1, Number 904, 2002 , pp. 9-9(1)

Publisher: Adis International

Anthrax vaccination is significantly associated with the development of joint disorders

Source: Inpharma, Volume 1, Number 1338, 2002 , pp. 21-21(1)

Publisher: Adis International

Anthrax vaccination is significantly associated with the development of joint disorders

Source: Reactions, Volume 1, Number 902, 2002 , pp. 4-4(1)

Publisher: Adis International

Infliximab is an effective treatment for patients with severe spondylarthropathy

Source: Inpharma, Volume 1, Number 1335, 2002 , pp. 16-16(1)

Publisher: Adis International

Inhibition of cyclo-oxygenase and lipoxygenase reviewed

Source: Inpharma, Volume 1, Number 1317, 2001 , pp. 2-2(1)

Publisher: Adis International